What are the latest findings on long‑term risk factors of taking Rinvoq (upadacitinib) 15 mg daily?

Long-Term Risk Factors of Rinvoq (Upadacitinib) 15 mg

The most critical long-term risks of upadacitinib 15 mg include venous thromboembolism (VTE), serious infections (particularly herpes zoster), and malignancies, with risk magnitude varying substantially based on patient age and cardiovascular risk factors.

Key Risk Categories

Venous Thromboembolism (VTE) and Cardiovascular Events

VTE risk is dose-dependent and significantly elevated in patients with pre-existing risk factors. 1 The British Society of Gastroenterology guidelines specifically note a black box warning for VTE and major adverse cardiovascular events (MACE) in higher-risk patients, though emerging experience continues to define this risk 1.

• Risk factors requiring careful evaluation include: age >65 years, history of VTE, inherited thrombophilias (factor V Leiden), obesity, recent surgery, immobility, exogenous estrogen use, current tobacco use, uncontrolled hypertension, and concomitant use of COX-2 inhibitors 1.
• In atopic dermatitis trials, VTE rates with upadacitinib were <0.1/100 patient-years, occurring only in patients with VTE history and risk factors 1.
• Adjudicated VTE incidence rates were 0.1 events/100 patient-years for upadacitinib 15 mg across 6 years of exposure 2.
• MACE rates were comparable between upadacitinib 15 mg and adalimumab in rheumatoid arthritis patients, with rates of 0.2 events/100 patient-years 2, 3.

Serious Infections

Herpes zoster reactivation represents the most consistent infection risk across all indications, with incidence rates 3-4 times higher than placebo. 1

• Serious infection rates with upadacitinib 15 mg range from 2.2-4.5 events/100 patient-years depending on indication 4.
• Herpes zoster rates are consistently elevated but less frequent with upadacitinib compared to other JAK inhibitors 1.
• In higher cardiovascular risk populations, serious infection rates were numerically higher with upadacitinib versus adalimumab 3.
• The European Medicines Agency restricted tofacitinib use in patients >65 years due to increased serious infection risk, though this specific restriction has not been uniformly applied to upadacitinib at the 15 mg dose 1.

Malignancy Risk

Overall malignancy rates excluding non-melanoma skin cancer (NMSC) remain low at 0.3 events/100 patient-years for upadacitinib 15 mg, with no increased risk compared to placebo or TNF inhibitors. 2, 5

• NMSC risk may be elevated, requiring regular skin examinations, particularly in high-risk populations 1.
• Lymphoma rates remain very low (<0.1 events/100 patient-years) 2.
• Malignancy risk is higher in patients aged ≥65 years and those with cardiovascular risk factors, though rates remain comparable to adalimumab 3.
• Most studies excluded patients with malignancy within 5 years prior to enrollment, limiting data on this population 1.

Hepatic and Laboratory Abnormalities

Hepatic transaminase elevations occur but are generally manageable and dose-dependent. 1, 5

• ALT elevations ≥3× upper limit of normal occurred in 2% of patients on upadacitinib 15 mg in ulcerative colitis maintenance trials 4.
• Upadacitinib should not be used in severe hepatic disease (Child-Pugh C); no dose adjustment needed for mild-moderate impairment 1.
• Neutropenia, anemia, and creatine phosphokinase (CPK) elevations show dose-dependent increases 1, 5.

Renal Considerations

For severe renal impairment (creatinine clearance <30 mL/min), the maximum recommended dose is 15 mg daily; no adjustment needed for mild-moderate impairment. 1

Risk Stratification Algorithm

Higher-Risk Patients (Requiring Enhanced Monitoring)

• Age ≥65 years with ≥1 cardiovascular risk factor 6, 3
• History of VTE or inherited thrombophilia 1
• Active or recent malignancy (within 5 years, excluding NMSC) 1
• Severe renal impairment (CrCl <30 mL/min) 1
• Current use of COX-2 inhibitors or prednisone >7.5 mg daily 1

Contraindications

• Severe active infections, including latent tuberculosis 1
• Severe hepatic disease (Child-Pugh C) 1
• Pregnancy and lactation (contraception required for both sexes; 4-week gap after last dose if pregnancy contemplated) 1
• Current malignancy under active treatment (except NMSC and cervical carcinoma in situ) 1

Monitoring Requirements

Baseline assessment must include: full blood count with differential, liver enzymes (ALT, AST), renal function, lipid panel, hepatitis B testing (anti-HBs, anti-HBc, HBsAg), tuberculosis screening, and skin examination for NMSC in at-risk patients 1.

• Counsel patients on VTE warning signs (leg swelling, chest pain, shortness of breath) 1.
• Regular skin examinations, especially in countries with high NMSC risk 1.
• Herpes zoster vaccination should be considered, though data on efficacy during JAK inhibitor therapy remain limited 1.

Long-Term Safety Data

Six-year safety data from atopic dermatitis trials show no new important safety signals with extended exposure. 2

• Treatment-emergent adverse events leading to death were rare (<0.1 events/100 patient-years for upadacitinib 15 mg) 2.
• The benefit-risk profile remains favorable in both short-term (~6 months) and long-term (5 years) treatment, independent of cardiovascular risk category 6.
• Real-world evidence confirms safety profiles similar to clinical trials, with acne and herpes simplex virus being the most common reasons for discontinuation 7.

Critical Pitfalls to Avoid

• Do not overlook VTE risk factors during initial assessment—this represents the most serious dose-dependent risk 1.
• Avoid combining with biologic DMARDs or potent immunosuppressants (cyclosporine, tacrolimus) due to increased immunosuppression risk 1.
• Do not use in patients with recurrent VTE unless they are on therapeutic anticoagulation 1.
• Screen for latent tuberculosis and hepatitis B before initiation—reactivation can occur 1.